Frontlight ResearchEarly access
Lung cancer trials in Hungary
55 of 57 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Farkasgyepű, Kecskemét, Szekszárd
- Age
- 18 years and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301 - Phase 2/3Not yet taking people in HungaryA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Gyöngyös
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00 - Phase 3Taking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Budapest XII, Győr, Kecskemét, Miskolc, Pécs, Salgótarján, Törökbálint
- Age
- 18 years and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Budapest XII, Budapest XIV, Farkasgyepű, Gyöngyös, Győr, Szekesfehervar, Szolnok, Törökbálint
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 2Taking peopleSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Where
- Budapest XII, Győr, Kecskemét, Szolnok, Törökbálint
- Age
- 18 years and over
- People
- 144 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00 - Phase 2/3Taking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Budapest Viii, Farkasgyepű, Gyula
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - Phase 3Taking peopleTrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Where
- Budapest, Gyöngyös
- Age
- 18 years and over
- People
- 363 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT06472245 - Phase 3Taking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Farkasgyepű, Gyula, Kaposvár, Szekesfehervar, Tatabánya
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Budapest VIII, Budapest XII, Salgótarján, Törökbálint
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 3Not yet taking people in HungaryBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Where
- Budapest, Gyöngyös, Kecskemét, Törökbálint
- Age
- 18 years and over
- People
- 550 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT07625644 - Phase 4CompletedDabrafenib and/or Trametinib Rollover Study
- Where
- Budapest XII, Debrecen
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 3Taking peopleA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Where
- Budapest, Farkasgyepű, Gyöngyös, Kecskemét, Székesfehérvár, Törökbálint
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07099898 - Phase 3Taking peoplePhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Where
- Budapest Viii, Budapest XII, Budapest XIV, Debrecen, Gyöngyös, Győr, Gyula, Kecskemét, Szolnok, Törökbálint
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00 - Phase 3Taking peopleDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Budapest XII, Debrecen, Gyula, Kecskemét, Szekszárd, Törökbálint
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00 - Phase 3Taking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Budapest XII, Gyöngyös, Győr, Kaposvár, Salgótarján, Szekesfehervar, Törökbálint
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Budapest, Mátraháza, Pécs, Törökbálint
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06793215 - Phase 3Taking peopleA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Budapest XII, Farkasgyepű, Kecskemét, Szolnok, Törökbálint
- Age
- 18 years and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00 - Phase 3Taking peopleA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Budapest XII, Budapest XIV, Farkasgyepű, Kecskemét
- Age
- 18 years and over
- People
- 1,264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00 - Phase 3CompletedA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Budapest XIV
- Age
- 18 years and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00 - Phase 3Taking peopleStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Budapest, Farkasgyepű
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00 - Phase 2Taking peopleStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Where
- Budapest Viii, Kecskemét, Tatabánya
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00 - Phase 2/3Taking peopleSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Where
- Budapest Viii, Budapest XII, Budapest XIV, Edelény, Kecskemét, Szolnok, Zalaegerszeg
- Age
- 18 years and over
- People
- 1,580 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00 - Phase 3Not yet taking people in HungaryClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Where
- Budapest, Miskolc
- Age
- 18 years to 90 years
- People
- 507 worldwide
- Run by
- ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00 - Phase 2/3Taking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Budapest VIII, Budapest XII, Farkasgyepű, Törökbálint
- Age
- 18 years and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - Phase 1/2CompletedKEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Where
- Budapest XII, Győr, Szolnok
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00